[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patient-preference\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patient-preference":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,71,107,140,163,194,220],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100433517","tradeoffs-in-patient-decision-making-about-rectal-cancer-treatment-benefits-compared-to-quality-of-life-100433517",false,"NCT04925154","Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.","PATHOS Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.","Pathos","Inclusion Criteria:\n\nGroup A\n\n* New rectal cancer patient\n* Operable patients\n* Capable adults older than 18 years of age\n* Capacity to sign a consent form\n* Capacity to answer questionnaires on an online platform Group B\n* Treating physician specialists\n* Capacity to sign a consent form\n* Capacity to answer questionnaires on an online platform\n\nExclusion Criteria:\n\nGroup A:\n\n* Patient unable to sign a consent form\n* Patients with metastasis\n* Recurrent tumours\n* Inability to answer questionnaires on an online platform\n* Inability to communicate in french or english\n\nGroup B:\n\n* Participant unable to sign a consent form\n* Inability to answer questionnaires on an online platform",true,"ALL","18 Years",{"count":21,"type":22},192,"ESTIMATED","3 Weeks","OBSERVATIONAL","This study is aiming to look into patients' treatment preferences and their socio economic background as well as the exploration of thought processes leading to these preferences. It will integrate, in two exploratory questionnaires, the three most common treatment schema (standard of care, non-operative management, surgery alone) all of which have been demonstrated efficacious.",[27],"Patient Preference",[29,30],"Colorectal cancer","Treatment preferences","RECRUITING","2026-05-11",{"date":34,"type":35},"2026-05-14","ACTUAL",{"date":37,"type":35},"2021-12-13",{"date":39,"type":22},"2028-01-01",{"name":41,"class":42},"Sir Mortimer B. Davis - Jewish General Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":18,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100516253","eliciting-informed-goals-of-care-in-elderly-patients-100516253","NCT06002113","Eliciting Informed Goals of Care in Elderly Patients","Assessment of Shared Decision-making Tool for Eliciting Informed Goals of Care in the Hospitalized Elderly (ASKMEGOC): A Randomized Clinical Trial","ASKMEGOC","Inclusion Criteria:\n\n* Hospitalized patients ≥ 80 years old with an acute medical or surgical condition admitted to any hospital ward\n* Previously or currently documented CODE STATUS preferences include any life sustaining therapies\n* Duration of admission ≥ 24 hours\n* English speaking, or translator present\n* Competent patient or substitute decision maker\n\nExclusion Criteria:\n\n* Treating physician, patient, or substitute decision maker declines\n* Documented resuscitation preferences for comfort or supportive care\n* New diagnosis of life-limiting illness on this hospital admission, for example, new diagnosis of metastatic cancer\n* Clinically unstable, admitted to an intensive care unit, or currently receiving acute life support treatment (mechanical ventilation, acute dialysis, or inotropic\u002Fvasopressor support)\n* Readmission after index hospitalization\n* Pre-existing need for chronic mechanical ventilation (invasive mechanical ventilation via tracheostomy \\> 90 days) or maintenance dialysis (peritoneal or hemodialysis \\> 90 days)","80 Years",{"count":54,"type":22},1200,"INTERVENTIONAL",[57],"NA","Patient-centered medical care considers a patient's values and goals for their health and well-being. Healthcare providers use this information to formulate a medical care plan that is aligned with these expectations. This shared-decision making process should occur with every medical decision, but it is especially important whenever decisions about end-of-life care are being considered. Eliciting patient preferences about resuscitation and life-support treatments in the event of life-threatening illnesses are considered to be a standard of excellent and appropriate medical care. Unfortunately, these discussions don't happen consistently and even when they do occur, are rarely ideal. The consequences can be devastating, often resulting in the delivery of unwanted medical care that can be associated with significant physical and mental suffering among patients and their families. In response to this problem, the investigators developed a novel tool to help guide these difficult conversations between healthcare providers and patients. The investigators previously tested this tool in a small group of hospitalized patients who found it acceptable and helpful. In this larger study, the investigators will compare how effective this tool is compared to usual care in ensuring hospitalized patients have their treatment preferences identified, documented and result in end-of-life care that is consistent with their preferences.",[60,27,61],"Goals of Care","End of Life","2025-11-18",{"date":64,"type":35},"2025-11-21",{"date":66,"type":35},"2023-10-03",{"date":68,"type":22},"2027-06-01",{"name":70,"class":42},"Royal Victoria Hospital, Canada",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100595707","the-vip3-very-old-intensive-care-patients-study-family-involvement-in-treatment-decisions-for-old-icu-patients-100595707","NCT07035951","The VIP3 (Very Old Intensive Care Patients) Study: Family Involvement in Treatment Decisions for Old ICU Patients","The VIP-3 (Very Old Intensive Care Patients) Study: Decision-making in the Older Intensive Care Unit (ICU) Patient: How Are Family Meetings Implemented Across Diverse Cultures in Europe?","VIP3","Inclusion Criteria:\n\n* Patients admitted to the Intensive Care Unit (ICU) of participating centres\n* Age 75 years and above\n* Expected Length of stay (LOS) \\> 3 days\n\nExclusion Criteria:\n\n* Refusal to participate\n* Limitation of treatment upon ICU arrival (other than Cardiopulmonary Resuscitation-CPR)\n* Planned admission","75 Years",{"count":81,"type":22},2000,"The demographics of the global population is changing with increasing numbers of elderly and co-morbid patients. As a result, more elderly patients will be admitted to the Intensive Care Unit (ICU), which will bring several ethical challenges. It is for this reason the investigators have chosen to focus on this historically neglected and important patient population.\n\nLittle is known about how family meetings are implemented in ICUs in Europe and other parts of the world. However, these meetings contribute to building trust between the family and the ICU team. They are a crucial component for planning and conducting a time limited trials as they provide the opportunity for shared-decision making with the ICU team and with other stakeholders.\n\nThe investigators plan to determine the current practice of communication between ICU staff and patients and their relatives. The investigators expect to find a substantial variation in approaches to family meetings. This information may then help design and further investigate targeted interventions enabling shared decision-making focused on family and patient values.\n\nThe investigators research aim is to to investigate whether Family meetings are used in ICUs across Europe and other regions and, if so, how they are conducted and the influence on patient-centred outcome measures.",[84,85,86,87,27],"Family Members","Critical Illness","Frailty","Communication",[89,90,91,92,93,94,95,96,97],"Elderly","Critical illness","communication","frailty","family meetings","Intensive care","critical care","shared decision making","patient preference","NOT_YET_RECRUITING","2025-06-16",{"date":101,"type":35},"2025-06-25",{"date":99,"type":22},{"date":104,"type":22},"2026-12",{"name":106,"class":42},"St George's, University of London",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":17,"sex":114,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":55,"phases":119,"briefSummary":120,"conditions":121,"keywords":125,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":43},"100534548","tens-unit-for-analgesia-during-iud-insertion-100534548","NCT06240260","TENS Unit for Analgesia During IUD Insertion","Utilization of Transcutaneous Electrical Nerve Stimulation (TENS) Unit for Analgesia During IUD Insertion: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Persons with a uterus desiring insertion of intrauterine device\n2. Able to provide informed consent\u002Fassent\n3. Age 12-50 years old\n4. Minors 12 years of age and older will be included in the study if postmenarchal\n\nExclusion Criteria:\n\n1. Unable to provide informed consent\u002Fassent\n2. Prior cervical procedure (ie loop electrosurgical excision procedure, LEEP)\n3. Concurrent cervical or intrauterine procedure (ie colposcopy or dilation and curettage)\n4. Cutaneous damage at the TENS electrode sites\n5. Chronic or pre-procedure use of opioids\n6. Chronic pain diagnosis\n7. Prior IUD insertion\n8. Any contraindication to intrauterine device (IUD):\n\n   1. Pregnancy\n   2. Uterine anomaly that distorts the uterine cavity\n   3. Acute pelvic inflammatory disease (PID)\n   4. Postpartum endometritis or infected abortion in the past 3 months\n   5. Unexplained abnormal uterine bleeding\n   6. Wilson's disease or copper allergy (contraindication to copper IUD only)\n   7. Breast cancer (contraindication to levonorgestrel IUD only","FEMALE","12 Years","50 Years",{"count":118,"type":22},40,[57],"Subjects will be screened over the phone or in Tufts GYN clinic for participation in the study. If eligible and interested in participating, written informed consent (and assent if applicable) will be obtained. After informed consent\u002Fassent, the patient will be enrolled in the study. The patient will decide if they desire to use TENS unit during IUD insertion appointment and inform the study team. The clinic visit will proceed as normal, with additional study proceedings as follows. The study personnel will complete the 'Background Questionnaire' with the patient prior to IUD insertion. During the IUD insertion appointment, study personnel will assist in collection of the 'Study visit' data collection form. This includes recording the patient's pain score at various time points throughout the insertion procedure:\n\n* anticipated pain during IUD insertion\n* baseline pain prior to insertion\n* speculum insertion\n* tenaculum placement\n* paracervical block administration (if performed)\n* cervical dilation (if performed)\n* uterine sounding\n* IUD insertion\n* 5 minutes after IUD insertion\n\nStudy personnel will also time the insertion procedure and collect additional data as outlined in the 'Study visit data collection form.' After IUD insertion, the participant will be asked to complete the 'Post-IUD Insertion Survey.' Once this survey is complete, this will conclude the study participation. Participation will last through the study visit only.\n\nAs part of the standard of care, a urine pregnancy test will be obtained and confirmed negative prior to IUD insertion. Patients will receive routine pain management modalities per shared decision-making with their clinical provider which may include NSAID administration, paracervical block, and heating pad.",[122,123,27,124],"IUD","Analgesia","Pain, Acute",[126,127,128,129,130],"iud","contraception","iud placement","pain management","teen","2025-06-03",{"date":133,"type":35},"2025-06-04",{"date":135,"type":35},"2024-04-30",{"date":137,"type":22},"2025-12-31",{"name":139,"class":42},"Tufts Medical Center",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":18,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":151,"studyType":24,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":43},"100555177","ct-angiography-plaque-characteristics-and-events-in-deferral-patients-by-invasive-fractional-flow-reserve-100555177","NCT06508697","CT-Angiography Plaque Characteristics and Events in Deferral Patients by Invasive Fractional Flow Reserve","CT-Angiography-Derived Plaque Characteristics on Cardiac Events in Deferral Patients by Invasive Fractional Flow Reserve","CAPTURE","Inclusion Criteria:\n\n* men and women aged ≥20 years,\n* patients having chronic coronary syndromes (CCS,\n* Coronary computed tomography angiography (CTA) was performed within 90 days before invasive coronary angiography (ICA) with fractional flow reserve (FFR) pressure measurement.\n\nExclusion Criteria:\n\n* patients with a history of coronary bypass grafting (CABG) because CABG changed local coronary flow dynamics,\n* patients with left-main disease,\n* patients with fractional flow reserve (FFR) in stented vessels due to inability to estimate plaque morphology in the stented lesion by coronary computed tomography angiography.","20 Years",{"count":150,"type":22},400,"3 Years","Fractional flow reserve (FFR)-guided PCI for chronic coronary syndromes (CCS) is reported to improve the outcomes compared with angiography-guided PCI. However, cardiac-events still occur in FFR-deferral patients in long-term follow-up. Coronary computed tomography angiography (CTA)-defined high-risk-plaque (HRP) is known to relate future cardiac events. The investigators hypothesized that CTA might identify plaque features linked to future cardiac events in deferral patients.",[27],"2025-01-02",{"date":156,"type":35},"2025-01-03",{"date":158,"type":22},"2025-01-30",{"date":160,"type":22},"2026-12-31",{"name":162,"class":42},"Fujita Health University",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":43},"100503467","switch-from-oral-therapy-to-long-acting-injectable-cabotegravir--rilpivirine-100503467","NCT05835635","Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine","Level of Satisfaction and Quality of Life in People Living With HIV in Chile, Who Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine","CABO-LA","Inclusion Criteria:\n\nAll patients who, according to the recommendations for use, can receive LA- injectable Cabotegravir +Rilpivirine therapy will be invited to participate in the study.\n\nRecommendations for use:\n\n* HIV-1 positive patients, on antiretroviral therapy\n* Older than 18 years of age at the time of signing the informed consent\n* Undetectable HIV viral load in the last 6 months\n* Willing to switch from oral to injectable therapy\n\nExclusion Criteria:\n\nThese criteria are defined for those patients who, according to the recommendations for use, cannot receive the therapy:\n\n* Previous virological failure\n* Any evidence of primary resistance or the presence of any major known INI or NNRTI resistance-associated mutation by any historical resistance test result.\n* Patients with decompensated pathology (physical or mental) or active opportunistic infection at the time of admission\n* Concomitant use with: rifampin, carbamazepine, oxcarbazepine, phenytoin and phenobarbital or any contraindication to one of the drugs of the study\n* Known hepatitis B co-infection\n* Pregnancy (There is insufficient data for people who become pregnant on CAB or those planning to conceive because available pregnancy PK data are limited (n = 3), and data on clinical outcomes in pregnancy are extremely limited. Therefore, CAB is Not Recommended for pregnant or nonpregnant people initiating or restarting ART or for those whose current regimen is not well tolerated and\u002For not fully suppressive)",{"count":172,"type":22},50,"This protocol will assess the level of satisfaction, acceptance of treatment and quality of life of patients with undetectable HIV who voluntarily change from oral to injectable antiretroviral treatment at 72 weeks of follow-up.",[175,27,176,177],"Patient Satisfaction","Quality of Life","Acceptability of Health Care",[179,180,181,182,183,184],"Quality of life","Acceptability","Satisfaction","Preference","HIV","Long acting- cabotegravir","2024-11-05",{"date":187,"type":35},"2024-11-07",{"date":189,"type":22},"2025-05-01",{"date":191,"type":22},"2026-05-01",{"name":193,"class":42},"Pontificia Universidad Catolica de Chile",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":17,"sex":18,"minAge":201,"maxAge":79,"enrollmentInfo":202,"targetDuration":4,"studyType":55,"phases":204,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":216,"leadSponsor":218,"locationsCount":43},"100404713","phase-4-the-prime-study-a-randomized-controlled-prospective-study-100404713","NCT04549935","The PRIME Study: A Randomized, Controlled, Prospective Study","A Randomized, Controlled, PRospective Study of the Effectiveness and Safety of the Ocular Therapeutix Dextenza (Dexamethasone Ophthalmic Insert) 0.4 mg for the treatMEnt of Post-operative Inflammation in Patients Who Plan to Undergo Refractive Lens Exchange (RLE)","Inclusion Criteria:\n\n* Any adult patient who is planned to undergo bilateral RLE surgery with BCVA 20\u002F30 or better\n* Willing and able to comply with clinic visits and study related procedures\n* Willing and able to sign the informed consent form\n\nExclusion Criteria:\n\n* Patients under the age of 22 or above the age of 75\n* Patients who are pregnant (must be ruled out in a women of child-bearing age with pregnancy test).\n* Patients with active infectious ocular or extraocular disease.\n* Patients actively treated with local or systemic immunosuppression including systemic corticosteriods\n* Paitents with know hypersensitivity to Dexamethasone\n* Patients with severe disease that warrants critical attentino, deemed unsafe for the study by the investigator\n* Patients with a history of ocular inflammation or macular edema\n* Patients with allergy or inability to receive intracameral antibiotic\n* Patients on systemic non-steroidal anti-inflammatory drugs (NSAID) grater than 1,200 mg\u002Fday\n* Patient with a corticosteriod implant (i.e. Ozurdex).\n* Patient with corneal pathology which pre-disposes them to unsatisfactory outcomes","22 Years",{"count":203,"type":22},20,[205],"PHASE4","To investigate the outcomes of patients undergoing bilateral RLE surgery with treatment of dexamethasone intracanilicular insert compared to topical standard care steroid. Desiged to look at patient preference comparing the insert to drops and will also look at patient outcomes including inflammatin and risk of cystoid macular edema post-operatively.",[27,208,209,210,211],"Patient Outcomes","Post-Operative Inflammation","Grade of Post-Operative Cystoid Macular Edema","Rate of Post-Operative Cystoid Macular Edema","2020-09-14",{"date":214,"type":35},"2020-09-16",{"date":212,"type":22},{"date":217,"type":22},"2021-08-27",{"name":219,"class":42},"Vance Thompson Vision - MT",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":17,"sex":18,"minAge":201,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":55,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":43},"100378312","phase-4-a-trial-evaluating-patient-preference-of-dropless-vs-drops-post-cataract-surgery-100378312","NCT04205916","A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery","A Prospective Trial Evaluating a Intracanalicular Insert Delivery System Compared to Traditional Topical Drops in Controlling Post-operative Pain and inFlammation in Subjects Undergoing Sequential Bilateral Cataract Surgery","CIMPLIFY","Inclusion Criteria:\n\n* A male or female subject in good general health (as determined by the Investigator), \\> 22 years of age at the time of the screening visit\n* A subject must be willing and able to sign informed consent\n* A woman of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test at screening and must be practicing an adequate method of birth control. Acceptable methods of birth control include intrauterine device (IUD), oral, dermal (\"patch\"), implant or injected contraceptives; tubal ligation; and barrier methods with spermicide.\n* A subject has the availability, willingness and sufficient cognitive awareness to comply with exam procedures and able to return for all scheduled study visits\n* A subject with a cataract for which routine phacoemulsification extraction and implantation of an intraocular lens has been planned\n\nExclusion Criteria:\n\n* A subject with a history of complications, adverse events, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in either eye\n* A subject with structural lid abnormalities (e.g., ectropion, entropion) in their schedule surgical eye\n* A subject with a puncta \\>0.9 mm prior to dilation in their scheduled surgical eye\n* A subject experiencing significant ocular pain or discomfort in either eye at the screening visit or on the day the plug is to be inserted\n* A subject with any moderate to severe lid, conjunctival or corneal findings in either eye at the screening visit\n* A subject with any signs of intraocular inflammation (cells\u002Fflare) in either eye at the screening visit\n* A subject with a known sensitivity to any of the study medications; A subject with a known or suspected allergy or hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), or to any component of the test article\n* A subject with a history as a steroid responder\n* A subject with capsule or zonular abnormalities with preoperative lens tilt and\u002For decentration (e.g., Marfan's syndrome), or may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome)\n* A subject has a history of ocular trauma in their scheduled surgical eye\n* A subject that has undergone prior intraocular surgery in the scheduled surgical eye within the last 6 months or laser surgery within three months prior to screening\n* A subject with pupil abnormalities (non-reactive, tonic pupils, abnormally shaped pupils, or pupils that do not dilate at least 3.5 mm under mesopic\u002Fscotopic conditions) in their scheduled surgical eye.\n* A subject with a corneal abnormality (e.g., stromal, epithelial or endothelial dystrophies) in their scheduled surgical eye\n* A subject with evidence of keratoconus or significant irregular astigmatism on pre-operative topography in their scheduled surgical eye\n* A subject with evidence of Epithelial Basement Membrane Dystrophy on slit-lamp exam\n* A subject that has been wearing Poly Methyl Metharcylate (PMMA) lenses within 6 months, gas permeable lenses within one month, or extended-wear or daily soft contact lens within 7 days of their scheduled surgery\n* A subject with an inability to achieve keratometric stability for contact lens wearers\n* A subject with a history of chronic\u002Frecurrent inflammatory eye disease (e.g., scleritis, uveitis, herpes keratitis) in either eye\n* A subject with uncontrolled glaucoma\n* A subject that requires an Limbal Relaxing Incision (LRI) or AI procedure before, during or after cataract surgery\n* A subject that may or is expected to undergo surgical intervention and\u002For ocular laser treatment prior to or during the study period\n* A subject that requires the use of systemic or ophthalmic Nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroid medications during the study period.\n* A subject that requires the use of system or ocular medications that may affect vision, ocular inflammation or pain\n* A subject with an acute or chronic disease, or illness, that would increase risk or confound study results (e.g., autoimmune disease, connective tissue disease, immunocompromised, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.)\n* A subject with an uncontrolled systemic disease: A potential subject in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study\n* A subject with diabetes that is poorly controlled\n* A subject currently participating or has participated in another clinical trial within 30 days prior to enrollment.\n\nIntra-Operative Exclusion Criteria (Surgical Complications):\n\n* Sulcus-sulcus or bag-sulcus fixation\n* Posterior capsular rupture or zonular dialysis\n* Disruption of anterior hyaloids face\n* Vitreous loss\n* Capsulorhexis tear\n* Floppy iris syndrome\n* Requirement for the use of trypan blue, capsular tension ring or other intraocular device other than the Intra ocular lens (IOL)\n* Inability to place IOL in capsular bag\n* Significant anterior chamber hyphema\n* Zonular rupture.","100 Years",{"count":172,"type":22},[205],"To evaluate the safety and ocular efficacy of Dextenza in combination with an intracameral antibiotic and NSAID in controlling post-operative ocular pain and inflammation compared to standard of care topical therapy in patients undergoing bilateral cataract surgery.",[27],"2019-12-17",{"date":235,"type":35},"2019-12-20",{"date":237,"type":35},"2019-11-04",{"date":239,"type":22},"2020-12-01",{"name":241,"class":42},"Ophthalmic Consultants of Long Island"]